Research And Markets Research And Markets
0 CHECKOUT

Candidiasis - Pipeline Review, H2 2015

  • ID: 3500436
  • October 2015
  • 140 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bakker Medical Srl
  • Cidara Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • iCo Therapeutics Inc.
  • Novabiotics Limited
  • Panacela Labs, Inc.
  • MORE

Candidiasis - Pipeline Review, H2 2015

Summary

The report ‘Candidiasis - Pipeline Review, H2 2015’, provides an overview of the Candidiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bakker Medical Srl
  • Cidara Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • iCo Therapeutics Inc.
  • Novabiotics Limited
  • Panacela Labs, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Candidiasis Overview

Therapeutics Development

Pipeline Products for Candidiasis - Overview

Pipeline Products for Candidiasis - Comparative Analysis

Candidiasis - Therapeutics under Development by Companies

Candidiasis - Therapeutics under Investigation by Universities/Institutes

Candidiasis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Candidiasis - Products under Development by Companies

Candidiasis - Products under Investigation by Universities/Institutes

Candidiasis - Companies Involved in Therapeutics Development

Aureogen Biosciences, Inc.

Bakker Medical Srl

Biomar Microbial Technologies

Cellceutix Corporation

Cidara Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

General Biologicals Corporation

GlaxoSmithKline Plc

Grupo Ferrer Internacional, S.A.

Hsiri Therapeutics, LLC

iCo Therapeutics Inc.

Nanomerics Ltd

Novabiotics Limited

NovaDigm Therapeutics, Inc.

Onxeo SA

Panacela Labs, Inc.

Scynexis, Inc.

Sealife PHARMA GMBH

Sequella, Inc.

Viamet Pharmaceuticals, Inc.

Wellstat Vaccines, LLC

Candidiasis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AC-17 - Drug Profile

amphotericin b - Drug Profile

amphotericin B - Drug Profile

arasertaconazole - Drug Profile

AUGC-10 - Drug Profile

AUGC-15 - Drug Profile

candida vaccine - Drug Profile

candida vaccine - Drug Profile

candidiasis oligosaccharide vaccine - Drug Profile

CD-101 - Drug Profile

CTIX-1502 - Drug Profile

DWP-06081 - Drug Profile

E-1210 - Drug Profile

E-1211 - Drug Profile

Forazoline A - Drug Profile

KSL-W - Drug Profile

MH-010 - Drug Profile

miconazole - Drug Profile

Monoclonal Antibodies to Target Fba for Candidiasis - Drug Profile

mutanobactins - Drug Profile

Myc-102 - Drug Profile

NDV-3 - Drug Profile

NDV-3A - Drug Profile

NP-339 - Drug Profile

obliquumol - Drug Profile

PAC-113 - Drug Profile

pegylated amphotericin B - Drug Profile

PMX-1408 - Drug Profile

PMX-1570 - Drug Profile

PMX-1576 - Drug Profile

PMX-1591 - Drug Profile

PMX-1625 - Drug Profile

PMX-519 - Drug Profile

PMX-70004 - Drug Profile

Prof-002 - Drug Profile

Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile

SCY-078 - Drug Profile

SLP-0901 - Drug Profile

SLP-0904 - Drug Profile

Small Molecule for Candidiasis - Drug Profile

Small Molecule for Fungal Infections - Drug Profile

Small Molecule for Systemic Candidiasis - Drug Profile

Small Molecules for Aspergillosis and Candidiasis - Drug Profile

Small Molecules for Candidiasis - Drug Profile

Small Molecules for Candidiasis - Drug Profile

Small Molecules for Candidiasis - Drug Profile

Small Molecules for Fungal Infections - Drug Profile

SQ-109 - Drug Profile

VT-1161 - Drug Profile

XELRYX-3 - Drug Profile

Candidiasis - Recent Pipeline Updates

Candidiasis - Dormant Projects

Candidiasis - Discontinued Products

Candidiasis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Candidiasis, H2 2015

Number of Products under Development for Candidiasis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2015

Candidiasis - Pipeline by Aureogen Biosciences, Inc., H2 2015

Candidiasis - Pipeline by Bakker Medical Srl, H2 2015

Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2015

Candidiasis - Pipeline by Cellceutix Corporation, H2 2015

Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2015

Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015

Candidiasis - Pipeline by Eisai Co., Ltd., H2 2015

Candidiasis - Pipeline by General Biologicals Corporation, H2 2015

Candidiasis - Pipeline by GlaxoSmithKline Plc, H2 2015

Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015

Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2015

Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2015

Candidiasis - Pipeline by Nanomerics Ltd, H2 2015

Candidiasis - Pipeline by Novabiotics Limited, H2 2015

Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2015

Candidiasis - Pipeline by Onxeo SA, H2 2015

Candidiasis - Pipeline by Panacela Labs, Inc., H2 2015

Candidiasis - Pipeline by Scynexis, Inc., H2 2015

Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2015

Candidiasis - Pipeline by Sequella, Inc., H2 2015

Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2015

Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Candidiasis Therapeutics - Recent Pipeline Updates, H2 2015

Candidiasis - Dormant Projects, H2 2015

Candidiasis - Dormant Projects (Contd..2), H2 2015

Candidiasis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Candidiasis, H2 2015

Number of Products under Development for Candidiasis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Aureogen Biosciences, Inc.
Bakker Medical Srl
Biomar Microbial Technologies
Cellceutix Corporation
Cidara Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
General Biologicals Corporation
GlaxoSmithKline Plc
Grupo Ferrer Internacional, S.A.
Hsiri Therapeutics, LLC
iCo Therapeutics Inc.
Nanomerics Ltd
Novabiotics Limited
NovaDigm Therapeutics, Inc.
Onxeo SA
Panacela Labs, Inc.
Scynexis, Inc.
Sealife PHARMA GMBH
Sequella, Inc.
Viamet Pharmaceuticals, Inc.
Wellstat Vaccines, LLC

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db